Source: Eur Respir J 2015; 46: 1740-1750
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Raghu Ganesh, Martinez Fernando J., Brown Kevin K., Costabel Ulrich, Cottin Vincent, Wells Athol U., Lancaster Lisa, Gibson Kevin F., Haddad Tarik, Agarwal Prasheen, Mack Michael, Dasgupta Bidisha, Nnane Ivo P., Flavin Susan K., Barnathan Elliot S.. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. Eur Respir J 2015; 46: 1740-1750

Member's Comments

No comment yet.

Related content which might interest you: SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772) Source: Eur Respir J, 52 (6) 1801130; 10.1183/13993003.01130-2018 Year: 2018 Idiopathic pulmonary fibrosis (IPF): observations from a Phase 2 trial of GLPG1205 (PINTA) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Longterm treatment effects of pulmonary hypertantion (PH) in idiopathic pulmonary fibrosis (IPF) patients by endothelin receptor blockade (Bosentan) Source: Eur Respir J 2007; 30: Suppl. 51, 120s Year: 2007 Results of a phase 2 study of GLPG1205 for idiopathic pulmonary fibrosis (PINTA) Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021 Upregulation of interleukin 13 receptor alpha 2 (IL-13RA2) expression in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 267s Year: 2005 LSC Abstract – Toll-like receptor 4 (TLR4) in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – IPF pathogenesis Year: 2015 Phase 2B dose selection of BG00011 for the treatment of idiopathic pulmonary fibrosis (IPF) Source: International Congress 2018 – Regenerative and anti-fibrotic approaches Year: 2018 Enhanced effects of pirfenidone on the early phase of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009 Bosentan in idiopathic pulmonary fibrosis (IPF) patients: the BUILD 1 study Source: Eur Respir J 2006; 28: Suppl. 50, 383s Year: 2006 Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (3) 1800663; 10.1183/13993003.00663-2018 Year: 2019 Extended analysis of phase III trial of pirfenidone: More pronounced effect in mild impairment of patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 CCR5 expression and CC chemokine levels in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 25: 701-707 Year: 2005 Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials Source: Eur Respir J 2016; 47: 243-253 Year: 2016 Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to CC chemokine ligand 21 Source: Eur Respir J 2007; 29: 1082-1093 Year: 2007 Blocking endothelin: breaking new ground Source: Eur Respir Rev 2008; 17: 24-29 Year: 2007 Exploratory analysis of phase III trial of pirfenidone: Most effective population in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Neutrophil chemokine receptor (CXCR1 and 2) gene expression and biopsy neutrophilia in severe exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 501s Year: 2001 Differential expression of stromal cell derived factor-1/CXC chemokine receptor 4 (SDF-1/CXCL12 – CXCR4) biological axis between idiopathic pulmonary fibrosis and interstitial pneumonia associated with collagen vascular disease: a bronchoalveolar la Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008